FDA seeks input on studying psychedelic ibogaine
The US Food and Drug Administration (FDA) is seeking public input on how to design early-phase clinical trials to evaluate therapeutic uses of the plant-derived psychoactive drug ibogaine.
Alongside the announcement, the agency said the National Institute on Drug Abuse (NIDA) will fund research on ibogaine to treat opioid use disorder (OUD) and that health authorities will prioritize studies of the drug in adults with OUD and post-traumatic stress disorder (PTSD).
"FDA welcomes INDs for ibogaine drug products and encourages sponsors to request a pre-IND meeting to discuss a specific proposed design," said FDA. "FDA has made no final determination as to the characteristics that would allow a trial of an ibogaine drug product to proceed, and it must evaluate whether each IND is supported by adequate scientific justification.
"However, based on a thorough review of available information, FDA has developed preliminary thinking on a design for an initial, open-label trial in which small groups of participants each receive a single dose of ibogaine, with the dose increasing from one group to the next," the agency added.
FDA’s evolving approach to psychedelics
There has been growing interested in developing psychedelic drugs, and while FDA has yet to approve any psychedelic drugs for any indication, it has taken several steps to advance their development in recent years. In April 2026, President Donald Trump signed an Executive Order directing federal agencies to accelerate the availability of psychedelics, including ibogaine compounds, to treat serious mental health disorders. Just days after order was signed, FDA announced it approved an investigational new drug (IND) submission for an early-phase clinical study of noribogaine hydrochloride, an ibogaine derivative, for the treatment of alcohol use disorder.
Three months later, FDA issued final guidance on considerations for clinical investigations evaluating psychedelic drugs. Then, in September, top FDA officials unveiled a “new framework” for psychedelic drugs in the New England Journal of Medicine, just days before hosting a public meeting on the potential future therapeutic use of psychedelic drugs. (RELATED: Psychedelics: FDA offers clarifications, compromises in final clinical trial guidance, Regulatory Focus 13 July 2026; FDA to consider ‘innovative approaches’ to psychedelic drug development, Regulatory Focus 10 September 2026).
Study design and feedback
FDA noted that, despite promising results, past studies have also raised concerns about potential prolongation of the heart rate-corrected QT (QTc) interval and the associated risks of life-threatening arrhythmia and neurotoxicity in nonclinical studies. The agency said there is significant uncertainty over the appropriate starting dose of ibogaine in people.
To address the uncertainty, regulators proposed conducting an initial clinical trial to assess whether the drug could be administered safely under close monitoring and evaluate the monitoring plan with the main objective to measure how the patient processes ibogaine and its active metabolite, noribogaine, in terms of both pharmacokinetics (PK) and pharmacodynamics (PD). The initial trial could also provide information on how both ibogaine and noribogaine affect the heart, and how participants tolerate them.
FDA also wants sponsors to consider the care setting when designing their clinical studies and stated that such studies should be conducted in inpatient care settings equipped to manage life-threatening arrhythmia, which would likely include continuous heart rhythm monitoring, a physician-led team trained in advanced cardiac life support, a defibrillator at the bedside, drugs to treat TdP, emergency cardiac pacing, and ventilator support. The agency also details how patients should be continuously monitored for potential prolongation of the heart rate-corrected QT intervals.
Regulators said that medications that prolong QTs-intervals, slow heart rate, interact with CYP2D6, or raise serotonin levels should be stopped before the ibogaine study is initiated. They also listed several scenarios where the study should be paused for review, including if the patient has a ventricular arrhythmia or a seizure, if their high QTc interval persists for more than two days, and if they develop suicidal thoughts or behavior.
Other important considerations proposed by FDA include limiting the trials to patients 18 to 55 years who have stopped taking psychiatric drugs. The agency also lists exclusion criteria for trial participants, including if they already have a high QTcF, have a family history of arrhythmia or cardiac death, or have exhibited suicidal thoughts and behavior.
FDA is seeking feedback on broader considerations regarding potential study designs, dose selection and escalation, safety, and ethics.
"Comments are most useful if they identify the specific element addressed [in the proposed study design], state whether it should continue to be part of FDA’s thinking, be modified, or if FDA should change its thinking about that element," said FDA. "Comments should also provide the data or clinical experience that supports that view."
Demystifying MISTIC
Trump and Health and Human Services (HHS) Secretary Robert Kennedy Jr. have both cited a 2024 Stanford study published in Nature, known as the Magnesium–Ibogaine: the Stanford Traumatic Injury to the CNS (MISTIC), to argue for more research into ibogaine. The study included 30 veterans with traumatic brain injury who traveled to Mexico to receive magnesium-ibogaine treatment over a 5-day period with promising results.
A recent report in Scientific American questioned Kennedy’s promotion of ibogaine. Kennedy has claimed that a researcher told him ibogaine was “the most promising treatment for depression and PTSD [post-traumatic stress disorder] that anybody’s ever seen.” However, many experts say these claims are overstated and note that there have been no head-to-head comparisons of ibogaine and other psychedelics, and caution that many of the promising results for the drug are preliminary.
Dennis Gorman, a professor of epidemiology and biostatistics at Texas A&M School of Public Health, wrote in the International Journal of Drug Policy in September that there are significant concerns about how the MISTIC study was conducted. He noted that the authors of the study appear to have adhered loosely to study registration requirements and did not include control conditions, which may have led to the exclusion of less promising findings. He also noted that three of the authors co-founded Ambio Life, which owns the treatment facility in Mexico where the study results come from.
"It would be naïve to think ibogaine policy is entirely guided by science and, like most drug policy (Ritter, 2021), this federal initiative was driven by a coalition of parties (politicians, veterans advocacy groups, psychiatric healthcare providers, pharmaceutical investors, advocates of psychedelics) with diverse interests," said Gorman. "But with regard to the quality of science moving forward, [the National Institutes of Health (NIH)] will be funding clinical trials of ibogaine, and one should expect these to be conducted in keeping with its implementation plan for the Government’s 2025 Gold Standard Science which emphases transparency, collaboration, skepticism, and subjecting hypotheses to genuine falsifiability tests (National Institutes for Health, 2025).
"Accordingly, the agency should ensure the trials it funds are reported as Registered Reports, as this procedure builds prospective registration and transparent reporting of changes in study design and methods into the publication process (Lakens et al., 2024)," he added. "Given the controversial nature of this research, the presence of high-profile ibogaine advocates, and the potential for conflicts of interests, NIH should also require that the studies it funds use blinded statistical analysis and include a minimum of one skeptic on the research team (Nuzzo, 2015)."
Potential conflicts of interest
Peter Pitts, president of the Center for Medicine in the Public Interest and former FDA associate commissioner, said the administration should be careful about potential conflicts of interest, as it touts the potential benefits of ibogaine while also overseeing its development and regulation.
"I support the FDA being both a partner with and regulator of drug developers," Pitts told Focus. "That being said, it’s an ethical and scientific tight-rope — but no one said it was going to be easy.
"The FDA must be able to play both roles to properly advance the public health," he added. "And this is clearly the case with psychedelics in general and ibogaine in particular."
Pitts said administration officials with potential financial interests in ibogaine should recuse themselves from any HHS or FDA interactions, especially with Kennedy. He also said any ibogaine developers touting relationships with the president or other administration officials should be called out.
"This is wrong and unethical," said Pitts. "Trying to 'lobby' the FDA to make their decisions on anything other than sound science is just plain wrong.
"The FDA’s call for public input is the right way to proceed," he added. "Asking the Administration to put its thumb on the regulatory scale is wrong in every instance — and would be wrong in this instance."
Stakeholders can comment on the RFI on www.regulations.gov under docket no. FDA-2026-N-10429 until 20 November.
